The American Society of Clinical Oncology (ASCO) has updated its recommendations regarding the use of pharmacological agents for breast cancer risk reduction. The new guidelines were developed by an expert panel after a review of the literature that identified relevant randomised trials published since ...
[3]NCCN Clinical Practice Guidelines in Breast Cancer.Version 2.2024. [4]Grace Mei Yee Choong et al., The impact of adjuvant endocrine therapy (AET) omission in ER-low (1-10%) early-stage breast cancer.. JCO 42, 513-513(2024). [5]Cai, Y. W., Shao, Z. M., & Yu, K. D. (...
参考文献 [1] Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Guideline and Rapid Update https://old-prod.asco.org/practice-patients/guidelines/breast-cancer#/9326 [2] Biomarkers for ...
参考文献 [1] Endocrine Treatment and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer Guideline and Rapid Update https://old-prod.asco.org/practice-patients/guidelines/breast-cancer#/9326 [2] Biomarkers for Systemic Therapy in Metastatic Breast Cancer Guideline and Rapid Upda...
[9]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 1.2024-January 25, 2024. [10]Buhl IK, Nart J, Papadovasilakis Z, et al. Predicting epirubicin response in Danish patients with b...
[6] Greenlee H ,DuPont-Reyes MJ, Balneaves LG, et al. (2017). Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment. CA Cancer J Clin. 2017 May 6;67(3):194-232. doi: 10.3322/caac.21397. ...
www.asco.org/breast-cancer-guidelines 一、晚期HER2阳性乳腺癌患者系统性疗法:ASCO临床实践指南更新(2018) (一)2018版意见 HER2+晚期乳腺癌患者建议采用抗HER2疗法,除非患者有临床性充血性心力衰竭,或有左心室射血分数过低,此时需做个案处理。 一线推荐药物包括:曲妥珠单抗(Trastuzumab)、帕妥珠单抗(pertuzumab)联合紫...
[8] CARDOSO F, KYRIAKIDES S, OHNO S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(8): 1194-1220. [9] BURSTEIN H J, LACCHETTI C, ANDERSON H, et al. Adjuvant endocrine therapy for women with hormone...
(3)RS>31,复发风险较高,化疗获益较大。 参考文献: 1. NCCN Breast cancer guidelines. V.1.2016. 2. Harris et al. J Clin Oncol. 2016 Feb 8. 3. Sparano et al. New Engl J Med. 2015 4. Paik et al. N Engl J Med. 2004. 5. Paik et al. J Clin Oncol. 2006....
[9]NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Breast Cancer. Version 1.2024-January 25, 2024. [10]Buhl IK, Nart J, Papadovasilakis Z, et al. Predicting epirubicin response in Danish patients with breast cancer. 2024 ASCO. 539. ...